Chengdu Kanghong Biotechnology Co., Ltd. et al. vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding PGR2021-00035 filed by Chengdu Kanghong Biotechnology Co., Ltd. et al. on 2021-01-07. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
PGR2021-00035
Filing Date
2021-01-07
Accorded Filing Date
2021-01-07
Institution Decision Date
—
Last Modified Date
2024-01-11
Proceeding Type
PGR
Termination Date
2021-06-25
Trial Status
Terminated
Parties & Counsel
Petitioner
Patent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Fishman, Deborahet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Terminated
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 17 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 10,828,345 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,888,601 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,986,511 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,730,794 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,975,045 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,707,506 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,253,572 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,559,564 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,268,730 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2025015266 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011614322 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011614348 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2011615619 | US Continuation / Sibling | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2012097019 A1 | PCT World Application | View Official Patent → |
| 🇺🇸 United States | US 9,254,338 B2 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.